Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triferic + Shohl's Solution for IRIDA
NCT02905981Phase 2Terminated
- Sponsor
- Rockwell Medical
- Start
- Jan 2017
- Primary completion
- Mar 2018
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of ferric pyrophosphate in iron-refractory iron deficiency anemia (IRIDA), sponsored by Rockwell Medical. Primary endpoint: Change in Hemoglobin (Hgb) at 4 months. Started Jan 2017; status: terminated.
02
Drugs
ferric pyrophosphate
03
Conditions
iron-refractory iron deficiency anemia (IRIDA)
Beyond the preview
Go deeper on NCT02905981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905981.